Levi & Korsinsky LLP
03/17/2026 | Press release | Distributed by Public on 03/17/2026 08:05
Orbit Turbulence: Ultragenyx Accused of Misleading Investors on Phase III Setrusumab Results
Ultragenyx Pharmaceutical Inc. promised a breakthrough. A rare disease drug. Strong data. And real hope for patients with brittle bone disease. Executives said their drug, setrusumab, was boosting bone density and would cut fractures. They sounded confident. Repeatedly.
In August 2023, Ultragenyx said Phase III trials were on track. Through 2024, they doubled down. Bone gains would translate into fewer fractures. The studies were well designed. The risk was controlled.
Then July 9, 2025 hit. Ultragenyx admitted the second interim analysis failed. The stock dropped about 25% in a day. Still, investors were told to stay calm.
But on December 29, the truth landed. Both Phase III studies failed their main goals. No meaningful fracture reduction. The stock collapsed about 42% in one trading day.
Now, shocked investors say they were misled. And more shareholders are joining the lawsuit.
Levi & Korsinsky LLP published this content on March 17, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 17, 2026 at 14:05 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]